
United Therapeutics Corp. (UTHR)
Last updated: 2026-10-21 14:07:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Summary
United Therapeutics Corp. (UTHR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $555.84, with a market capitalization of $23.30B and a P/E ratio of 18.12. Over the past 52 weeks, its price has ranged from $409.07 to $609.35. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$23.30B | |
$553.63 | |
$609.35 | |
$9.11 | |
$553.88 | |
18.50K | |
707.83K | |
18.12 | |
$609.35 | |
$409.07 | |
-- | |
-- |
United Therapeutics Corp. (UTHR) Stock Price Today
United Therapeutics Corp. (UTHR) is currently trading at $555.84 as of 2026-10-21 14:05:00, up 0.35% ($1.96) from the previous close of $553.88
During today's regular trading session, UTHR has traded between $9.11 and $609.35, with a trading volume of 18.50K shares. The current price is near the upper end of today's range.
United Therapeutics Corp. (UTHR) 7-Day Stock Price Change
Over the past seven days, United Therapeutics Corp. (UTHR) moved from $550.10 to $555.84, representing a gain of 1.04% ($5.74).
The stock traded between $523.95 and $564.97 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 631.04 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
UTHR 52-Week Price Position
Position in Range: 73.3%
UTHR is currently trading at $555.84, placing it 73.3% of the way from its 52-week low of $409.07 to its 52-week high of $609.35. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is United Therapeutics Corp. (UTHR)?
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
United Therapeutics Corp. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 1400 |
| Exchange | NASDAQ |
| Company Website |
How to Buy United Therapeutics Corp. (UTHR) Stock on MEXC
Eligible investors can buy real shares of United Therapeutics Corp. (UTHR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is United Therapeutics Corp. (UTHR) stock price today?
2.Is UTHR stock going up or down today?
3.What is UTHR pre-market price?
4.What is UTHR after-hours price?
5.Is UTHR stock trading now?
6.Where does UTHR sit relative to its 52-week high and low?
7.What sector is United Therapeutics Corp. in?
8.What is United Therapeutics Corp.'s market capitalization and where is it listed?
9.How is UTHR valued in terms of P/E ratio and EPS?
10.Does United Therapeutics Corp. pay a dividend?
Explore More US Stocks
Search Stocks
UTHR Stock Calculator
Estimate the value between UTHR shares and USD.
UTHR Shares to USD
1.00 UTHR shares = 555.839 USD
Calculations are estimates based on the latest available price and are for reference only.



